Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Biotechnol Bioeng. 2012 Apr 8;109(9):2357–2368. doi: 10.1002/bit.24488

Figure 6.

Figure 6

Safranin-O staining of cell-laden PEG hydrogel. A: Treated with standard chondrogenic condition with TGF-β1 only from week 1 to 4. B: Treated with FGF-2 for week 1, then TGF-β1 from week 2 to 4. C: Treated with FGF-2/TGF-β1 for week 1, then TGF-β1 from week 2 to 4. D: Proliferating cells in PEG hydrogel with FGF-2/TGF-β1 synergistic treatment at week 4. E: Human chondrocytes in PEG hydrogel photoencapsulated at high cell density (20×106 cells/mL) at week 3 (E1 & E2) and 4 (E3 & E4). E2 and E4 show chondrocytes with no proteoglycan production at week 3 and 4, respectively. Scale bars: A, B, C, E1, E3 = 200 μm; D, E2, E4 = 50 μm.